Kyverna Therapeutics, Inc.

Contributing Author

Recent Articles by Kyverna Therapeutics, Inc.

Jun-22	Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition KYTX GlobeNewswire
Jun-03	Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis KYTX GlobeNewswire
May-18	Kyverna Therapeutics Names Greg Martini as Chief Financial Officer KYTX -10.01% GlobeNewswire
May-14	Kyverna Therapeutics to Present at Upcoming Investor Conferences KYTX GlobeNewswire
May-12	Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results KYTX KYTX +5.38% GlobeNewswire
May-04	Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer KYTX GlobeNewswire
Apr-21	Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting KYTX -13.69% KYTX +5.36% GlobeNewswire
Apr-20	Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks KYTX +13.29% GlobeNewswire
Apr-09	Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 KYTX GlobeNewswire
Mar-26	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results KYTX GlobeNewswire
Mar-05	Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 KYTX -5.41% GlobeNewswire
Mar-03	Kyverna Therapeutics to Participate in Upcoming March Investor Conferences KYTX -5.76% GlobeNewswire
Feb-24	Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors KYTX GlobeNewswire
Feb-03	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer KYTX GlobeNewswire
Jan-12	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference KYTX GlobeNewswire
Jan-05	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference KYTX -7.30% GlobeNewswire
Dec-17	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock KYTX -32.52% GlobeNewswire
Dec-15	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock KYTX +23.23% KYTX -5.36% GlobeNewswire
Dec-15	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome KYTX +23.23% GlobeNewswire
Dec-14	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome KYTX GlobeNewswire
Nov-12	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results KYTX KYTX -11.60% GlobeNewswire
Nov-10	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference KYTX GlobeNewswire
Nov-03	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance KYTX GlobeNewswire
Oct-29	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 KYTX -5.78% GlobeNewswire
Oct-25	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 KYTX GlobeNewswire
Oct-22	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis KYTX -6.58% GlobeNewswire
Sep-24	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS KYTX GlobeNewswire
Sep-15	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 KYTX GlobeNewswire
Aug-28	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event KYTX GlobeNewswire
Aug-25	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September KYTX GlobeNewswire
Aug-12	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results KYTX KYTX +14.90% GlobeNewswire

Kyverna Therapeutics, Inc.

Recent Articles by Kyverna Therapeutics, Inc.

Upgrade your Finviz experience